Carprofen-induced depletion of proton motive force reverses TetK-mediated doxycycline resistance in methicillin-resistant Staphylococcus pseudintermedius.
Adenosine Triphosphate
/ metabolism
Anti-Bacterial Agents
/ pharmacology
Bacterial Proteins
/ metabolism
Carbazoles
/ pharmacology
Doxycycline
/ pharmacology
Drug Resistance, Multiple, Bacterial
Drug Synergism
Ion Transport
Membrane Transport Proteins
/ metabolism
Methicillin Resistance
NADP
/ metabolism
Protons
Staphylococcus
/ drug effects
Tetracycline Resistance
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
28 11 2019
28 11 2019
Historique:
received:
14
05
2019
accepted:
31
10
2019
entrez:
30
11
2019
pubmed:
30
11
2019
medline:
5
11
2020
Statut:
epublish
Résumé
We previously showed that doxycycline (DOX) and carprofen (CPF), a veterinary non-steroidal anti-inflammatory drug, have synergistic antimicrobial activity against methicillin-resistant Staphylococcus pseudintermedius (MRSP) carrying the tetracycline resistance determinant TetK. To elucidate the molecular mechanism of this synergy, we investigated the effects of the two drugs, individually and in combination, using a comprehensive approach including RNA sequencing, two-dimensional differential in-gel electrophoresis, macromolecule biosynthesis assays and fluorescence spectroscopy. Exposure of TetK-positive MRSP to CPF alone resulted in upregulation of pathways that generate ATP and NADH, and promote the proton gradient. We showed that CPF is a proton carrier that dissipates the electrochemical potential of the membrane. In the presence of both CPF and DOX, the energy compensation strategy was attenuated by downregulation of all the processes involved, such as citric acid cycle, oxidative phosphorylation and ATP-providing arginine deiminase pathway. Furthermore, protein biosynthesis inhibition increased from 20% under DOX exposure alone to 75% upon simultaneous exposure to CPF. We conclude that synergistic interaction of the drugs restores DOX susceptibility in MRSP by compromising proton-motive-force-dependent TetK-mediated efflux of the antibiotic. MRSP is unable to counterbalance CPF-mediated PMF depletion by cellular metabolic adaptations, resulting in intracellular accumulation of DOX and inhibition of protein biosynthesis.
Identifiants
pubmed: 31780689
doi: 10.1038/s41598-019-54091-4
pii: 10.1038/s41598-019-54091-4
pmc: PMC6882848
doi:
Substances chimiques
Anti-Bacterial Agents
0
Bacterial Proteins
0
Carbazoles
0
Membrane Transport Proteins
0
Protons
0
NADP
53-59-8
Adenosine Triphosphate
8L70Q75FXE
carprofen
FFL0D546HO
Doxycycline
N12000U13O
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
17834Références
Infect Genet Evol. 2018 Apr;59:16-22
pubmed: 29413881
Vet Microbiol. 2011 Jun 2;150(3-4):338-43
pubmed: 21420256
Nucleic Acids Res. 2015 Jan;43(Database issue):D447-52
pubmed: 25352553
Nucleic Acids Res. 2013 May 1;41(10):e108
pubmed: 23558742
Microbiol Spectr. 2018 Mar;6(2):
pubmed: 29573258
Chem Biol. 2014 Apr 24;21(4):481-487
pubmed: 24631121
Antimicrob Agents Chemother. 2008 Mar;52(3):980-90
pubmed: 18086846
J Antimicrob Chemother. 2010 Jun;65(6):1145-54
pubmed: 20348087
Can J Vet Res. 2014 Jul;78(3):183-92
pubmed: 24982549
J Gen Microbiol. 1984 Jan;130(1):69-76
pubmed: 6423769
Clin Microbiol Rev. 2015 Apr;28(2):337-418
pubmed: 25788514
Biochim Biophys Acta. 1981 Dec 30;639(3-4):225-42
pubmed: 7039674
Methods Mol Biol. 2017;1548:181-190
pubmed: 28013504
Open Microbiol J. 2013;7:59-71
pubmed: 23569469
Nucleic Acids Res. 2015 Sep 3;43(15):e97
pubmed: 25925576
Microbiol Rev. 1986 Sep;50(3):314-52
pubmed: 3534538
Xenobiotica. 2006 Oct-Nov;36(10-11):877-901
pubmed: 17118913
Appl Microbiol Biotechnol. 2006 Apr;70(3):261-72
pubmed: 16432742
BMC Microbiol. 2009 May 18;9:95
pubmed: 19450265
J Biol Chem. 1990 Mar 25;265(9):4809-13
pubmed: 2156856
Nat Chem Biol. 2011 Jun;7(6):348-50
pubmed: 21516114
Antimicrob Agents Chemother. 1993 Feb;37(2):191-8
pubmed: 8452348
Proc Natl Acad Sci U S A. 2008 Mar 4;105(9):3461-6
pubmed: 18305163
IUBMB Life. 1999 Aug;48(2):187-97
pubmed: 10794596
Nucleic Acids Res. 2018 Jan 4;46(D1):D633-D639
pubmed: 29059334
Cell Mol Life Sci. 2010 Feb;67(3):419-31
pubmed: 19862477
J Bacteriol. 2008 Nov;190(21):7275-84
pubmed: 18757537
J Inorg Biochem. 2006 May;100(5-6):1015-23
pubmed: 16412515
J Appl Microbiol. 2000 Sep;89(3):526-31
pubmed: 11021586
Biotechnol Bioeng. 2005 Dec 30;92(7):850-64
pubmed: 16155945
Stand Genomic Sci. 2011 Oct 15;5(1):168-93
pubmed: 22180819
PLoS One. 2012;7(8):e41329
pubmed: 22876285
Proc Natl Acad Sci U S A. 2010 Jul 6;107(27):12281-6
pubmed: 20566861
Gigascience. 2018 Jan 1;7(1):1-6
pubmed: 29220494
Genome Biol. 2014 Feb 03;15(2):R29
pubmed: 24485249
CRC Crit Rev Biochem. 1985;19(2):145-90
pubmed: 2415299
Nucleic Acids Res. 1999 Jan 1;27(1):29-34
pubmed: 9847135
Sci Rep. 2019 Mar 6;9(1):3679
pubmed: 30842436
Infect Immun. 2018 Sep 21;86(10):
pubmed: 30061377
Annu Rev Microbiol. 1985;39:219-42
pubmed: 2998266
Genome Biol. 2013 Apr 25;14(4):R36
pubmed: 23618408
BMC Vet Res. 2016 Jun 24;12(1):126
pubmed: 27342694
J Bacteriol. 2013 Oct;195(20):4580-91
pubmed: 23913327
Appl Environ Microbiol. 1996 Jan;62(1):178-83
pubmed: 16535209